BR112022002229A2 - Composições de trofinetida - Google Patents
Composições de trofinetidaInfo
- Publication number
- BR112022002229A2 BR112022002229A2 BR112022002229A BR112022002229A BR112022002229A2 BR 112022002229 A2 BR112022002229 A2 BR 112022002229A2 BR 112022002229 A BR112022002229 A BR 112022002229A BR 112022002229 A BR112022002229 A BR 112022002229A BR 112022002229 A2 BR112022002229 A2 BR 112022002229A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- trophinetide
- compounds
- products
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
- B01J21/06—Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
- B01J21/18—Carbon
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
- B01J23/44—Palladium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Materials Engineering (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882998P | 2019-08-05 | 2019-08-05 | |
| PCT/US2020/044733 WO2021026066A1 (en) | 2019-08-05 | 2020-08-03 | Compositions of trofinetide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022002229A2 true BR112022002229A2 (pt) | 2022-04-19 |
Family
ID=74502416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022002229A BR112022002229A2 (pt) | 2019-08-05 | 2020-08-03 | Composições de trofinetida |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11370755B2 (https=) |
| EP (1) | EP4009962A4 (https=) |
| JP (2) | JP2022543391A (https=) |
| KR (1) | KR20220059479A (https=) |
| CN (1) | CN114667136A (https=) |
| AU (1) | AU2020324396B2 (https=) |
| BR (1) | BR112022002229A2 (https=) |
| CA (1) | CA3149633A1 (https=) |
| CL (1) | CL2022000301A1 (https=) |
| CO (1) | CO2022002616A2 (https=) |
| IL (1) | IL290324A (https=) |
| JO (1) | JOP20220027A1 (https=) |
| MX (1) | MX2022001505A (https=) |
| MY (1) | MY206115A (https=) |
| SA (1) | SA522431585B1 (https=) |
| WO (1) | WO2021026066A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220059479A (ko) | 2019-08-05 | 2022-05-10 | 뉴렌 파마슈티컬즈 리미티드 | 트로피네타이드의 조성물 |
| MX2023014655A (es) * | 2021-07-12 | 2024-01-12 | Acadia Pharm Inc | Formas cristalinas de trofinetida. |
| WO2025169163A1 (en) * | 2024-02-10 | 2025-08-14 | Teadus Pharma Private Limited | Method for the synthesis of trofinetide and its analogues |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2573765B1 (fr) * | 1984-11-23 | 1988-06-10 | Solvay | Procede pour la synthese de peptides |
| US8637567B2 (en) | 2001-05-24 | 2014-01-28 | Neuren Pharmaceuticals Ltd. | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid |
| US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
| US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
| ATE435852T1 (de) | 2001-05-24 | 2009-07-15 | Neuren Pharmaceuticals Ltd | Gpe-analoga und peptidomimetika |
| US7863304B2 (en) | 2001-05-24 | 2011-01-04 | Neuren Pharmaceuticals Limited | Analogs of glycyl-prolyl-glutamate |
| EP1888618A4 (en) * | 2005-05-23 | 2009-07-15 | Neuren Pharmaceuticals Ltd | Analogs of glycyl-prolyl-glutamate |
| WO2007106555A2 (en) | 2006-03-14 | 2007-09-20 | Neuren Pharmaceuticals Limited | Oral formulations of glycyl-2-methylprolyl-glutamate |
| EP2060580A1 (en) * | 2007-11-19 | 2009-05-20 | SOLVAY (Société Anonyme) | Process for the manufacture of persilylated peptides |
| AU2012209466C1 (en) * | 2011-01-27 | 2016-06-23 | Neuren Pharmaceuticals Limited | Treatment of Autism Spectrum Disorders using Glycyl-L-2-Methylprolyl-L-Glutamic Acid |
| US20150224164A1 (en) * | 2013-11-26 | 2015-08-13 | Neuren Pharmaceuticals Limited | Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid |
| KR20220059479A (ko) | 2019-08-05 | 2022-05-10 | 뉴렌 파마슈티컬즈 리미티드 | 트로피네타이드의 조성물 |
-
2020
- 2020-08-03 KR KR1020227006982A patent/KR20220059479A/ko active Pending
- 2020-08-03 MX MX2022001505A patent/MX2022001505A/es unknown
- 2020-08-03 EP EP20850753.3A patent/EP4009962A4/en active Pending
- 2020-08-03 WO PCT/US2020/044733 patent/WO2021026066A1/en not_active Ceased
- 2020-08-03 MY MYPI2022000626A patent/MY206115A/en unknown
- 2020-08-03 CA CA3149633A patent/CA3149633A1/en active Pending
- 2020-08-03 BR BR112022002229A patent/BR112022002229A2/pt unknown
- 2020-08-03 AU AU2020324396A patent/AU2020324396B2/en active Active
- 2020-08-03 CN CN202080062340.0A patent/CN114667136A/zh active Pending
- 2020-08-03 JP JP2022506639A patent/JP2022543391A/ja not_active Withdrawn
-
2021
- 2021-06-14 US US17/347,135 patent/US11370755B2/en active Active
-
2022
- 2022-02-01 JO JOP/2022/0027A patent/JOP20220027A1/ar unknown
- 2022-02-03 SA SA522431585A patent/SA522431585B1/ar unknown
- 2022-02-03 IL IL290324A patent/IL290324A/en unknown
- 2022-02-04 CL CL2022000301A patent/CL2022000301A1/es unknown
- 2022-03-04 CO CONC2022/0002616A patent/CO2022002616A2/es unknown
- 2022-06-23 US US17/847,736 patent/US11866406B2/en active Active
-
2023
- 2023-11-21 US US18/516,604 patent/US12297172B2/en active Active
-
2026
- 2026-01-13 JP JP2026003598A patent/JP2026063085A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MY206115A (en) | 2024-11-29 |
| US12297172B2 (en) | 2025-05-13 |
| CA3149633A1 (en) | 2021-02-11 |
| EP4009962A1 (en) | 2022-06-15 |
| JP2022543391A (ja) | 2022-10-12 |
| US11866406B2 (en) | 2024-01-09 |
| MX2022001505A (es) | 2022-03-11 |
| US20240109841A1 (en) | 2024-04-04 |
| KR20220059479A (ko) | 2022-05-10 |
| EP4009962A4 (en) | 2023-08-09 |
| CO2022002616A2 (es) | 2022-06-10 |
| US20220324799A1 (en) | 2022-10-13 |
| CL2022000301A1 (es) | 2022-09-20 |
| JP2026063085A (ja) | 2026-04-10 |
| SA522431585B1 (ar) | 2025-02-13 |
| AU2020324396B2 (en) | 2025-07-03 |
| US20220055987A1 (en) | 2022-02-24 |
| AU2020324396A1 (en) | 2022-03-10 |
| IL290324A (en) | 2022-04-01 |
| JOP20220027A1 (ar) | 2023-01-30 |
| CN114667136A (zh) | 2022-06-24 |
| US11370755B2 (en) | 2022-06-28 |
| WO2021026066A1 (en) | 2021-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| BR112021018456A2 (pt) | Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento | |
| BR112022002229A2 (pt) | Composições de trofinetida | |
| CL2018002516A1 (es) | Inhibidores de mcl-1 indólicos sustituidos. | |
| BR112017006705A2 (pt) | inibidores de biossíntese de sulfato de heparan para o tratamento de doenças | |
| BR112018074185A2 (pt) | 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas | |
| BR112016005270A2 (pt) | compostos de aza-piridona, composições farmacêuticas e seus usos | |
| EP4356969A3 (en) | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections | |
| BR112015022462A2 (pt) | inibidores de ido | |
| BR112017015536A2 (pt) | ?métodos de purificação de canabinoides, suas composições e kits? | |
| WO2025049274A3 (en) | Tetracyclic derivatives, compositions and methods thereof | |
| BR112022005627A2 (pt) | Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica e uso de um composto | |
| BR112015001028A2 (pt) | antagonistas de receptor 5-ht3 | |
| PE20191477A1 (es) | Nuevo compuesto heterociclico, su metodo de preparacion y composicion farmaceutica que lo comprende | |
| BR112022010082A2 (pt) | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica | |
| MX2022010693A (es) | Compuestos, composiciones y metodos para inhibidores de la proteina quinasa que interactua con el receptor i para el tratamiento de enfermedades. | |
| CL2022003703A1 (es) | Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos | |
| MX2021008510A (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina. | |
| ZA202001295B (en) | Thiazolopyridine derivatives as adenosine receptor antagonists | |
| CL2018000856A1 (es) | Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida. | |
| JOP20210332A1 (ar) | عقاقير أولية لمعدلات المستقبل nmda | |
| UY29161A1 (es) | Nuevos heterociclos | |
| EP4467198A3 (en) | Fused tricyclic pyridazinone compounds and prodrugs thereof useful to treat orthomyxovirus infections | |
| ECSP21062210A (es) | Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias | |
| MX2025001068A (es) | Derivados arilos tricíclicos, y composiciones y métodos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |